Associated Psychological Disorders and Impairment of Emotional Regulation among Patients with Multiple Sclerosis
https://doi.org/10.31363/2313-7053-2019-4-2-19-28
Abstract
The review of data from the available literature cites the results of studies of psychological disorders comorbid to multiple sclerosis and highlights scientific papers detailing domestic and foreign research. The high prevalence of affective and adaptive impairment is linked both to the neurophysiological particularities of this chronic, progressive, neurodegenerative illness and to psychological factors — individual personality traits and the attitude of those afflicted to their illness, to the change in their social functioning and to their prognosis. It is demonstrated that patients with multiple sclerosis have a significantly higher frequency of depressive and anxiety disorders than the general population, which suggests the need for an integrated, personalized approach to people with this illness.
About the Authors
M. T. Andreeva
St. Petersburg City Center for Multiple Sclerosis and Other Autoimmune Diseases; Saint-Petersburg State University
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
T. A. Karavaeva
V. M. Bekhterev National Research Medical Center for Psychiatry and Neurology; Saint-Petersburg State University
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
References
1. Boyko O.V., Tatarinova M.YU., Popova E.V., Guseva M.R., Boyko A.N., Gusev E.I. The improvement of quality of life of patients with multiple sclerosis over 15-year period. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018; 2:23-28 (In Russ.). doi.org/10.17116/jnevro201811808223
2. Vasileva A.V., Karavaeva T.A., Lukoshkina E.P., Karpov A.V. Socio-psychological risk factors for the development of posttraumatic stress disorder in patients with rectum cancer, who undergone colostomia. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. 2018; 2:44-53 (In Russ.).
3. Kaplin A., Carroll K., Rasseyannyi skleroz. V kn.: C. Lyketsos, P. Rabins, J. Lipsey, P. Slavney. Psychiatric aspects of neurologic diseases. Practical approaches to patient care. MEDpress — inform. 2017:116-136. (In Russ.).
4. Karvasarskii B.D. Klinicheskaya psikhologiya: uchebnik dlya vuzov. 5-e izd. SPb.: Piter. 2016; 896 (In Russ.).
5. Luriya A.R. Vysshie korkovye funktsii cheloveka. — SPb.: Piter. 2019;768:47-104 (In Russ.).
6. Martynikhin I.A. Epidemiologiya, osobennosti i spetsificheskie faktory riska rasstroistv depressivnogo spektra u zhenshchin. Zhenskoe psikhicheskoe zdorove — ot isterii k genderno-sensitivnomu podkhodu. Pod obshchei redaktsiei: N. G. Neznanova. Avtory-sostaviteli: A.V. Vasileva, T.A. Karavaeva. Sankt-Peterburg: Izdatel’skii Dom «Alef-Press». 2018; 208-222 (In Russ.).
7. Nikolaev E.L., Karavaeva T.A., Vasileva N.V., Chekhlatyi E.I. The personalized approach in medical and psychological support of multiple sclerosis patients. Vestnik psikhoterapii. 2018; 65(70) 86-97 (In Russ.).
8. Nikolaev E.L., Karavaeva T.A., Vasileva N.V. Medical and psychological support of multiple sclerosis patients: basic principles and objectives. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. 2018; 1:120-124 (In Russ.).
9. Sirota N.A., Moskovchenko D.V., Yaltonskii V.M., Yaltonskaya A.V Аnxiety on the progression of oncological diseases: modern theoretical concepts and approaches. Meditsinskaya psikhologiya v Rossii: elektron. nauch. zhurn. 2016; 6:41 (data obrashenia: 30.04.2018 (In Russ.).
10. Khomskaya E.D. Neiropsikhologiya: uchebnik dlya vuzov. 4-e izd. — SPb.: Piter. 2018; 496 (In Russ.).
11. Shmidt T.E., Yakhno N.N. Rasseyannyi skleroz: rukovodstvo dlya vrachei. 3-e izd. — M.: MEDpress — inform. 2012; 272:13 — 64 (In Russ.).
12. Anderson D, Ellenberg J, Leventhal C, Reingold S, Rodriguez M, Silberberg D. Revised estimate of the prevalence of multiple sclerosis in the united states. Ann Neurol. 1992; 31(3):333-336. doi:10.1002/ana.410310317
13. Aronson K, Cleghorn G, Goldenberg E. Assistance arrangements and use of services among persons with multiple sclerosis and their care-givers. Disabil Rehabil. 1996; 18(7):354-361. doi:10.3109/09638289609165894
14. Association between bipolar affective disorder and multiple sclerosis. American Journal of Psychiatry. 1986; 143(1):94-95. doi:10.1176/ajp.143.1.94
15. Bakshi R, Czarnecki D, Shaikh Z et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport. 2000; 11(6):1153-1158. doi:10.1097/00001756-200004270-00003
16. Barak Y, Achiron A, Elizur A, Gabbay U, Noy S, Sarova-Pinhas I. Sexual dysfunction in relapsing-remitting multiple aclerosis: Clinical, psychological and MRI correlates. J Neuroimmunol. 1995; 56-63:56-56. doi:10.1016/0165-5728(95)99052-k
17. Benedict R, Carone D, Bakshi R. Correlating Brain Atrophy With Cognitive Dysfunction, Mood Disturbances, and Personality Disorder in Multiple Sclerosis. Journal of Neuroimaging. 2004; 14:36S-45S. doi:10.1111/j.1552-6569.2004.tb00277.x
18. Boeschoten R, Braamse A, Beekman A et al. Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2017; 372:331-341. doi:10.1016/j.jns.2016.11.067
19. Brown S. The mental symptoms of multiple sclerosis. Arch Neurol Psychiatry 1922; 7(5):629.
20. doi:10.1001/archneurpsyc.1922.02190110080008
21. Butler E, Matcham F, Chalder T. A systematic review of anxiety amongst people with Multiple Sclerosis. Mult Scler Relat Disord. 2016; 10:145-168. doi:10.1016/j.msard.2016.10.003
22. Chahraoui K, Pinoit J, Viegas N, Adnet J, Bonin B, Moreau T. Alexithymie et liens avec la depression et lanxiete dans la sclerose en plaques. Rev Neu¬rol (Paris). 2008; 164(3):242-245. doi:10.1016/j.neurol.2007.09.006
23. Chalah M, Ayache S. Psychiatric event in multiple sclerosis: could it be the tip of the iceberg?. Revista Brasileira de Psiquiatria. 2017; 39(4):365-368. doi:10.1590/1516-4446-2016-2105
24. Chalfant A, Bryant R, Fulcher G. Posttraumatic stress disorder following diagnosis of multiple sclerosis. J Trauma Stress. 2004; 17(5):423-428. doi:10.1023/b:jots.0000048955.65891.4c
25. Charcot J, Seigerson G. “Lectures 6 through 8,” in Lectures on the Diseases of the Nervous System. Delivered at La Salpetriere. Am J Med Sci. 1877; 148(4):532-533. doi:10.1097/00000441-187710000-00035
26. Cottrell S, Wilson S. Original Papers: The affective symptomatology of disseminated sclerosis: a study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry. 1926; s1-7(25):1-30. doi:10.1136/jnnp.s1-7.25.1
27. Dantzer R. Cytokine-Induced Sickness Behavior: Where Do We Stand? Brain Behav Immun. 2001; 15(1):7-24. doi:10.1006/brbi.2000.0613
28. Diaz-Olavarrieta C, Cummings J, Velazquez J, Garcia de al Cadena C. Neuropsychiatric Mani-festations of Multiple Sclerosis. J Neuropsychiatry Clin Neurosci. 1999; 11(1):51-57. doi:10.1176/jnp.11.1.51
29. Duncan A, Malcolm-Smith S, Ameen O, Solms M. Changing definitions of euphoria in multiple sclerosis: A short report. Multiple Sclerosis Journal. 2014; 21(6):776-779. doi:10.1177/1352458514549400
30. Duncan A, Malcolm-Smith S, Ameen O, Solms M. The Incidence of Euphoria in Multiple Sclerosis: Artefact of Measure. Mult Scler Int. 20116 2016:1-8. doi:10.1155/2016/5738425
31. Feinstein A, Magalhaes S, Richard J, Audet B, Moore C. The link between multiple sclerosis and depression. Nature Reviews Neurology. 2014; 10(9):507-517. doi:10.1038/nrneurol.2014.139
32. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002; 59(5):674-678. doi:10.1212/wnl.59.5.674
33. Feinstein A. The Neuropsychiatry of Multiple Sclerosis. The Canadian Journal of Psychiatry. 2004; 49(3):157-163. doi:10.1177/070674370404900302
34. Figved N, Klevan G, Myhr K et al. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatr Scand. 2005; 112(6):463-468. doi:10.1111/j.1600-0447.2005.00624.x
35. Filippi M, Alberoni M, Martinelli V et al. Influence of Clinical Variables on Neuropsychological Performance in Multiple Sclerosis. Eur Neurol. 1994; 34(6):324-328. doi:10.1159/000117071
36. Fishman I, Benedict R, Bakshi R, Priore R, Weinstock-Guttman B. Construct Validity and Frequency of Euphoria Sclerotica in Multiple Sclerosis. J Neuropsychiatry Clin Neurosci. 2004; 16(3):350-356. doi:10.1176/jnp.16.3.350
37. Fisk J, Pontefract A, Ritvo P, Archibald C, Murray T. The Impact of Fatigue on Patients with Multiple Sclerosis. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 1994; 21(01):9-14. doi:10.1017/s0317167100048691
38. Gay M, Bungener C, Thomas S et al. Anxiety, emotional processing and depression in people with multiple sclerosis. BMC Neurol. 2017; 17(1). doi:10.1186/s12883-017-0803-8
39. Gay M, Vrignaud P, Garitte C, Meunier C. Predictors of depression in multiple sclerosis patients. Acta Neurol Scand. 2010; 121(3):161-170. doi:10.1111/j.1600-0404.2009.01232.x
40. George M, Kellner C, Bernstein H, Goust J. A Magnetic Resonance Imaging Investigation into Mood Disorders in Multiple Sclerosis. J Nerv Ment Dis. 1994; 182(7)408-411. doi:10.1097/00005053-199407000-00008
41. Gerolimatos LA, Edelstein BA. Predictors of health anxiety among older and young adults. International Psychogeriatrics. 2012; 24(12):1998-2008. doi: http://dx.doi.org/10.1017/S1041610212001329.
42. Goodin D. The epidemiology of multiple sclero¬sis. Neuroepidemiology. 206:; 173-206. doi:10.1016/b978-0-12-802973-2.00011-2
43. Haussleiter I, Brune M, Juckel G. Review: Psycho-pathology in multiple sclerosis: diagnosis, preva-lence and treatment. Ther Adv Neurol Disord. 2009; 2(1):13-29. doi:10.1177/1756285608100325
44. Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. The Lancet Neurology. 2015; 14(4):406-419. doi:10.1016/s1474-4422(14)70305-9
45. Henry A, Tourbah A, Camus G et al. Anxiety and depression in patients with multiple sclero¬sis: The mediating effects of perceived social support. Mult Scler Relat Disord. 2019; 27:46-51. doi:10.1016/j.msard.2018.09.03925.
46. Haussleiter I, Brune M, Juckel G. Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment. Ther Adv Neurol Disord. 2009; 2(1):13-29. doi:10.1177/1756285608100325
47. Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized con-trolled trial. Neurology. 1995; 45(7):1277-1285. doi:10.1212/wnl.45.7.1277
48. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW, and the CHAMPS Study Group. N Engl J Med. 2000; 343:898-904. Am J Ophthalmol. 2001; 131(1):154-155. doi:10.1016/s0002-9394(00)00915-6
49. Johnson K, Brooks B, Cohen J et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-con-trolled trial. Neurology. 1995; 45(7):1268-1276. doi:10.1212/wnl.45.7.1268
50. Jopson N, Moss-Morris R. The role of illness severity and illness representations in adjusting to multiple sclerosis. J Psychosom Res. 2003; 54(6):503-511. doi:10.1016/s0022-3999(02)00455-Klapper J. Interferon beta treatment of multiple sclerosis. Neurology. 1994; 44(1):188-188. doi:10.1212/wnl.44.1.188-a
51. Kubzansky LD, Thurston RC. Emotional vitality and incident coronary heart disease: Benefits of healthy psychological functioning. Archives of General Psychiatry. 2007; 64(12):1393-1401. doi: http://dx.doi.org/10.1001/archpsyc.64.12.1393
52. Lee B, Dantzer R, Langley K et al. A Cytokine-Based Neuroimmunologic Mechanism of Cancer-Related Symptoms. Neuroimmunomodulation. 2004; 11(5):279-292. doi:10.1159/000079408
53. Lublin F, Reingold S, Cohen J et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014; 83(3):278-286. doi:10.1212/wnl.0000000000000560
54. Lynch S, Kroencke D, Denney D. The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping, and hope. Multiple Sclerosis. 2001; 7(6):411-416. doi:10.1191/135245801701566998
55. Malik U, Makower D, Wadler S. Interferon-mediated fatigue. Cancer. 2001; 92(S6):1664-1668. doi:10.1002/1097-0142(20010915)92:6+<1664::aid-cncr1494>3.0.co;2-9
56. Minden S. Mood disorders in multiple sclerosis: diagnosis and treatment. Journal of Neurovirology. 2000; 6(2):160-167.
57. Minden S, Schiffer R. Affective Disorders in Multiple Sclerosis Review and Recommendations for Clinical Research. Arch Neurol. 1990; 47(1):98-104. doi:10.1001/archneur.1990.00530010124031
58. Minden S, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry. 1987; 9(6):426-434. doi:10.1016/0163-8343(87)90052-1
59. Mohr D, Hart S, Goldberg A. Effects of Treatment for Depression on Fatigue in Multiple Sclerosis. Psychosom Med. 2003; 65(4):542-547. doi:10.1097/01.psy.0000074757.11682.96
60. Moller A, Wiedemann G, Rohde U, Backmund H, Sonntag A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand. 1994; 89(2):117-121. doi:10.1111/j.1600-0447.1994.tb01497.x
61. Moriya R, Kutsumi M. Fatigue in Japanese people with multiple sclerosis. Nurs Health Sci. 2010; 12(4):421-428. doi:10.1111/j.1442-2018.2010.00554.x
62. Noy S, Achiron A, Gabbay U et al. A new approach to affective symptoms in relapsing-remitting multiple sclerosis. Compr Psychiatry. 1995; 36(5):390-395. doi:10.1016/s0010-440x(95)90121-3
63. Ostacoli L, Carletto S, Borghi M et al. Prevalence and Significant Determinants of Post-traumatic Stress Disorder in a Large Sample of Patients with Multiple Sclerosis. J Clin Psychol Med Settings. 2012; 20(2):240-246. doi:10.1007/s10880-012-9323-239.
64. Panda S, Das R, Srivastava K, Ratnam A, Sharma N. Psychiatric comorbidity in multiple sclerosis. Neurol Neurochir Pol. 2018; 52(6):704-709. doi:10.1016/j.pjnns.2018.09.003
65. Patten S, Marrie R, Carta M. Depression in multiple sclerosis. International Review of Psychiatry. 2017; 29(5):463-472. doi:10.1080/09540261.2017.1 322555
66. Patten S, Metz L. Interferon 1a and depression in secondary progressive MS: Data from the SPEC-TRIMS Trial. Neurology. 2002; 59(5):744-746. doi:10.1212/wnl.59.5.744
67. Patten S, Metz L. Interferon fi-1a and depression in relapsing — remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Multiple Sclerosis Journal. 2001; 7(4):243-248. doi:10.1177/135245850100700406
68. Patten S, Metz L, Reimer M. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Multiple Sclerosis. 2000; 6(2):115-120. doi:10.1191/135245800678827536
69. Pujol J, Bello J, Deus J, Marti-Vilalta J, Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology. 1997; 49(4):1105-1110. doi:10.1212/wnl.49.4.1105
70. Rabins P, Brooks B, O’Donnell P et al. Structural brain correlates of emotional disorder in multiple sclerisis. Brain. 1986; 109(4):585-597. doi:10.1093/brain/109.4.585
71. Rabkin J, Albert S, Del Bene M et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology. 2005; 65(1):62-67. doi:10.1212/01.wnl.0000167187.14501.0c
72. Raison C, Demetrashvili M, Capuron L, Miller A. Neuropsychiatric Adverse Effects of Interferon-alpha. CNS Drugs. 2005; 19(2):105-123. doi:10.2165/00023210-200519020-00002
73. Reischies F. Cerebral Magnetic Resonance Imaging Findings in Multiple Sclerosis. Arch Neurol. 1988; 45(10):1114. doi:10.1001/archneur.1988.00520340068014
74. Sabatini U, Pozzilli C, Pantano P et al. Involvement of the limbic system in multiple sclerosis patients with depressive disorders. Biol Psychiatry. 1996; 39(11):970-975. doi:10.1016/0006-3223(95)00291-%
75. Sadovnick A, Eisen K, Ebers G, Paty D. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991; 41(8):1193-1193. doi:10.1212/wnl.41.8.1193
76. Sai-Halasz A. Psychic Alterations in Disseminated Sclerosis A General, Statistical and Rorschach-Test Study on 200 Patients. Eur Neurol. 1956; 132(2-3):129-154. doi:10.1159/000139628
77. Sanfilipo M, Benedict R, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology. 2006; 66(5):685-692. doi:10.1212/01.wnl.0000201238.93586.d9
78. Schaefer M, Engelbrechta M, Gut O et al. Interferon alpha (IFNa) and psychiatric syndromes. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2002; 26(4):731-746. doi:10.1016/s0278-5846(01)00324-4
79. Schiffer R. Multiple Sclerosis and Affective Disorder. Arch Neurol. 1988;45(12):1345. doi:10.1001/ archneur.1988.00520360063013
80. Siegert R. Depression in multiple sclerosis: a review. Journal of Neurology, Neurosurgery & Psychiatry. 2005; 76(4):469-475. doi:10.1136/jnnp.2004.054635
81. Sugar C, Nadell R. Mental symptoms in multiple sclerosis. J Nerv Ment Dis. 1943; 98(3):267-280. doi:10.1097/00005053-194309000-00004
82. Tedman B, Young C, Williams I. Assessment of depression in patients with motor neuron disease and other neurologically disabling illness. J Neurol Sci. 1997; 152s75s79. doi:10.1016/s0022-510x(97)00249-9
83. Trask P, Paterson A, Esper P, Pau J, Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology. 2004; 13(8)526-536. doi:10.1002/pon.770
84. Vercoulen J. The Measurement of Fatigue in Patients With Multiple Sclerosis. Arch Neurol. 1996; 53(7):642. doi:10.1001/arch-neur.1996.00550070080014
85. Weinshenker B, Bass B, Rice G et al. The natural history of multiple sclerosi : a geographically based study. Brain. 1989; 112(1):133-146. doi:10.1093/brain/112.1.133
86. Wierenga K, Lehto R, Given B. Emotion Regulation in Chronic Disease Populations: An Integrative Re-view. Res Theory Nurs Pract. 2017; 31(3):247-271. doi:10.1891/1541-6577.31.3.247
87. Whitlock F, Siskind M. Depression as a major symptom of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 1980; 43(10):861-865. doi:10.1136/jnnp.43.10.861
88. Wood B, van der Mei I, Ponsonby A et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Multiple Sclerosis Journal. 2012; 19(2):217-224. doi:10.1177/1352458512450351
89. Zephir H, De Seze J, Stojkovic T et al. Multiple sclerosis and depression: influence of interferon b therapy. Multiple Sclerosis Journal. 2003; 9(3):284-288. doi:10.1191/1352458503ms915oaa
Review
For citations:
Andreeva M.T., Karavaeva T.A. Associated Psychological Disorders and Impairment of Emotional Regulation among Patients with Multiple Sclerosis. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2019;(4-2):19-28. (In Russ.) https://doi.org/10.31363/2313-7053-2019-4-2-19-28
Views:
8143
Email this article 